TDTilmann Ditting

Tilmann Ditting

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Tilmann Ditting has a total of 95 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Abstract 082: Intrarenal Nacl Boli Cause Longlasting Inhibition of Renal Sympathetic Nerve Activity (RSNA)

    by Martin Hindermann, Kristina Rodionova, Amelie Dietz, Tilmann Ditting, Christian Ott, Roland Schmieder, Kerstin Amann, Roland Veelken

    Afferent renal nerve fibers from the kidney likely counterregulate salt sensitive blood pressure increases by decreasing renal sympathetic nerve activity. We recently reported on a long-lasting tonic sympatho-inhibition due to intrarenal afferent renal nerve stimulation eliciting a TRPV1 dependent neuro-humoral pathway. We wanted to test the hypothesis that sodium influences this afferent sympatho-depressory mechanism. Groups of anesthetized SD rats (n=8) were equipped with femoral catheters (blood pressure (BP) & heart rate (HR) recording, drug application), a renal arterial catheter for intrarenal administration (IRA) of high salt (10 % NaCl, 10 μl) or Capsaicin (CAP 3.3, 6.6, 10, 33*10-7 M, 10 μl) and a bipolar electrode for RSNA recordings; eventually an intravenous (iv) bolus of the NK1-receptor blocker RP67580 (10*10-3M, 15 μl) was given. Cultured dorsal root ganglion neurons (Th11-L2) of rats with renal afferents were investigated in current clamp mode to assess action potential generation or in voltage clamp mode to investigate inward currents during 10 sec superperfusion to 4.5 % NaCl or equiosmotic mannitol. solution Results are given in mean±SEM. IRA high salt and IRA CAP decreased RSNA from baseline 4.1±0.6 μV*sec to 2.2±0.8 μV*sec (10% NaCl, p<0.05) and 3.9±0.5 μV*sec to 0.9±0.2 μV*sec (CAP, p<0.01). Suppressed RSNA in high salt groups and CAP could be unmasked by systemic (i.v.) administration of the NK1-blocker (2.7±1.8 μV*sec to 5.8±2.2 μV*sec; p<0.05 (10% NaCl); 1.0±0.2 μV*sec to 6.1±1.5 μV*sec; p<0.01 (CAP)). Cultured renal neurons exhibited production of action potentials (3.5±0.8*, from baseline, p<0.05) and increased sustained inward currents from baseline during exposure to NaCl 4.5 % (-10708.8±3546.5 pA*, from baseline, p<0.05). No responses to equiosmolar mannitol. Increased intrarenal sodium concentrations might induce long-lasting sympatho-depression via a neuro-humoral TRPV1 dependent and tachykinin mediated afferent nerve pathway from the kidney. Impairment of this sympatho-depressory mechanism could be involved in salt sensitive hypertension.

  • The effect of renal denervation in moderate treatment-resistant hypertension with confirmed medication adherence

    by Christian Ott, Felix Mahfoud, Axel Schmid, Sebastian Ewen, Stefan W. Toennes, Markus R. Meyer, Andreas G. Helfer, Hans H. Maurer, Tilmann Ditting, Roland Veelken, et al.

    Data on the blood pressure (BP)-lowering effect of renal denervation (RDN) in moderate treatment-resistant hypertension (TRH) are limited. Moreover, change of adherence to medication, as one potential confounder of BP response, has never been analyzed rigorously in this group of patients. We analyzed the effect of RDN on BP in patients with moderate TRH who were retrospectively found to be completely adherent to their antihypertensive medication. Our study cohort comprised 40 patients with moderate TRH [office BP ≥ 140/90 but <160/100 mmHg and 24-h ambulatory BP monitoring (ABPM) ≥130/80 mmHg] who underwent catheter-based RDN. Further major inclusion criterion was complete adherence to their medication (≥80% intake of their prescribed antihypertensive drugs) at baseline (assessed by retrospective toxicological analysis). Six months after RDN, office BP was reduced by −10/−6 mmHg (SBP: 149 ± 6 vs. 139 ± 15 mmHg; DBP: 81 ± 12 vs. 75 ± 10 mmHg; both P < 0.001) and 24-h ABPM by −7/−4 mmHg (SBP: 150 ± 14 vs. 143 ± 16 mmHg, P = 0.005; DBP: 82 ± 10 vs. 78 ± 9 mmHg, P = 0.009). Number of prescribed antihypertensive medication [6.0 (5.0–6.0) vs. 5.5 (5.0–6.0), P = 0.013] and adherence rate (95.2 ± 7.6 vs. 91.7 ± 13.9%, P = 0.065) was slightly reduced 6 months after RDN, both likely to underestimate the true BP reduction. Thus, our data indicate that even after given full respect to drug adherence as potential confounder of BP response after RDN, both office and 24-h ABPM were substantially reduced in patients with moderate TRH.


  • OS 28-03 SECRETORY CAPACITY OF PANCREATIC BETA CELLS IS ENHANCED 6 MONTHS AFTER RENAL DENERVATION IN TREATMENT RESISTANT HYPERTENSIVE PATIENTS

    by Christian Ott, Iris Kistner, Axel Schmid, Stefanie Friedrich, Tilmann Ditting, Roland Veelken, Felix Mahfoud, Michael Böhm, Michael Uder, Roland Schmieder

    Renal denervation (RDN) lowers blood pressure (BP) by interruption of sympathetic nerve activity. A high sympathetic tone increases not only BP but also decreases pancreatic beta cell insulin secretion. Hence, the objective of the study was to analyze whether RDN improves secretory capacity of beta cells.In 40 patients (7 diabetics, 19 prediabetics, 14 non diabetics) with treatment resistant hypertension (defined by office BP ≥ 140/90 mmHg and diagnosis confirmed with 24-h ambulatory BP ≥ 130/80 mmHg), insulin secretion was measured before and 6 months after RDN (Simplicity flex catheter, Medtronic) by glucagon test. At each time point blood was sampled prior to glucagon administration and 6 minutes after intravenous injection of 1 ml glucagon for measurement of C-peptide, insulin and proinsulin (by ELISA).In these 40 patients (mean age 58 ± 12 years, mean office BP 154 ± 22 mmHg / 89 ± 14 mmHg while on 5.2 ± 1.4 antihypertensive drugs) office systolic and diastolic BP was significantly reduced 6 months after RDN (both p < 0.01). Fasting plasma glucose and HbA1c level was significantly reduced 6 month after RDN (both p < 0.01). Six months after RDN, the increase of C-peptide concentration and insulin concentration after glucagon injection was significantly higher compared to before RDN (both p < 0.05).Thus, our data indicate an improved pancreatic beta cell function after RDN in patients with treatment resistant hypertension.

  • OS 29-03 INCREASED NEUROKININ RELEASE FROM AFFERENT RENAL NERVES IS ACCOMPANIED BY DECREASED AFFERENT ELECTRIC ACTIVITY

    by Tilmann Ditting, Kristina Rodionova, Sonja Heinlein, Karl Friedrich Hilgers, Christian Ott, Roland Schmieder, Kerstin Amann, Roland Veelken

    Objective: Afferent renal nerves exhibit a dual function. They influence intrarenal immunological processes by release of neurokinins like CGRP and control central sympathetic outflow via afferent electrical activity. The former seems to be important in renal inflammation whereas the sympathetic modulation by afferent electrical activity is not fully understood in cardiovascular disease and hypertension. Hence, we hypothesized that augmented effects of CGRP in renal inflammation occur with increased afferent renal nerve activity. Design and Method: As inflammatory model, normotensive renal inflammation (RI) was induced by i.v. injection of 1.75 mg/kg BW OX-7 antibody to rats to avoid confounding blood pressure effects by choosing a hypertensive model in the first place. Animals were investigated neurophysiologically and pathomorphologically using standard techniques 6 days after RI induction. Results: Blood pressure (BP) was normal, hence confounding BP effects were unlikely. RI rats exhibited albuminuria (61 ± 6 μg/24 h), infiltration of macrophages in the interstitium (26 ± 4 cells/hp field) and glomeruli (3.7 ± 0.6 cells/glomerular X-section). Pretreatment with the CGRP antagonist rCGRP 8-37 (15 nmol/kg) significantly reduced proteinuria and macrophage infiltration suggesting increased activity of CGRP. In an in-vitro assay, renal RI tissue exhibited increased CGRP release (14 ± 3 pg/ml vs. controls 6.8 ± 2.8 pg/ml; p < 0.05, n = 8). RI tissue from renally denervated rats showed no CGRP. Afferent renal nerve activity (ARNA; spikes/sec) was unexpectedly lower in RI compared to controls (8.0 ± 1.8 vs. 27.4 ± 4.1 Hz, n = 6, p < 0.05). On the other hand, the burst-frequency renal sympathetic nerve activity (RSNA) in RI was significantly higher than in controls (14.7 ± 0.9 vs. 11.5 ± 0.9 bursts/sec; n = 6, p < 0.05). Conclusions: In contrast to our hypothesis increased release of neurogenic CGRP aggravating RI occurred with decreased ARNA. Increased RSNA pointed to a reduced tonic inhibition by ARNA. The latter mechanism might worsen sympathetic dysregulation and renal damage as in hypertension.

  • MPS 11-09 Renal Afferent Peptidergic Neurons in the Control of the Autonomous Nervous System – What are Primary Stimuli?

    by Tilmann Ditting, Kristina Rodionova, Sonja Heinlein, Karl Friedrich Hilgers, Christian Ott, Roland Schmieder, Kerstin Amann, Roland Veelken

  • Complex reinnervation pattern after unilateral renal denervation in rats

    by Kristina Rodionova, Christian Fiedler, Franziska Guenther, Eric Grouzmann, Winfried Neuhuber, Michael J. M. Fischer, Christian Ott, Peter Linz, Wolfgang Freisinger, Sonja Heinlein, et al.

    Renal denervation (DNX) is a treatment for resistant arterial hypertension. Efferent sympathetic nerves regrow, but reinnervation by renal afferent nerves has only recently been shown in the renal pelvis of rats after unilateral DNX. We examined intrarenal perivascular afferent and sympathetic efferent nerves after unilateral surgical DNX. Tyrosine hydroxylase (TH), CGRP, and smooth muscle actin were identified in kidney sections from 12 Sprague-Dawley rats, to distinguish afferents, efferents, and vasculature. DNX kidneys and nondenervated kidneys were examined 1, 4, and 12 wk after DNX. Tissue levels of CGRP and norepinephrine (NE) were measured with ELISA and mass spectrometry, respectively. DNX decreased TH and CGRP labeling by 90% and 95%, respectively ( P < 0.05) within 1 wk. After 12 wk TH and CGRP labeling returned to baseline with a shift toward afferent innervation ( P < 0.05). Nondenervated kidneys showed a doubling of both labels within 12 wk ( P < 0.05). CGRP content decreased by 72% [3.2 ± 0.3 vs. 0.9 ± 0.2 ng/gkidney; P < 0.05] and NA by 78% [1.1 ± 0.1 vs. 0.2 ± 0.1 pmol/mgkidney; P < 0.05] 1 wk after DNX. After 12 wk, CGRP, but not NE, content in DNX kidneys was fully recovered, with no changes in the nondenervated kidneys. The use of phenol in the DNX procedure did not influence this result. We found morphological reinnervation and transmitter recovery of afferents within 12 wk after DNX. Despite morphological evidence of sympathetic regrowth, NE content did not fully recover. These results suggest a long-term net surplus of afferent influence on the DNX kidney may be contributing to the blood pressure lowering effect of DNX.


  • IMPROVEMENT OF ALBUMINURIA AFTER RENAL DENERVATION

    by Roland E. Schmieder, Felix Mahfoud, Axel Schmid, Tilmann Ditting, Roland Veelken, Sebastian Ewen, Christian Ukena, Michael Uder, Michael Boehm, Christian Ott


  • 1.1 Anatomie

    by Keikawus Arastéh, Hanns-Wolf Baenkler, Christiane Bieber, Roland Brandt, Tushar Chatterjee, Thorsten Dill, Tilmann Ditting, Wolfgang Eich, Sabine Ernst, Dieter Fritze, et al.

  • 1.1 Anatomie

    by Keikawus Arastéh, Hanns-Wolf Baenkler, Christiane Bieber, Roland Brandt, Tushar Chatterjee, Thorsten Dill, Tilmann Ditting, Wolfgang Eich, Sabine Ernst, Dieter Fritze, et al.

  • Renal Denervation in a Hypertensive Patient With End‐Stage Renal Disease and Small Arteries: A Direction for Future Research

    by Christian Ott, Axel Schmid, Tilmann Ditting, Paul A. Sobotka, Roland Veelken, Michael Uder, Roland E. Schmieder

    J Clin Hypertens (Greenwich). 2012;14:799–801. ©2012 Wiley Periodicals, Inc.